![]() | ![]() |
Formats:
|
||||||||||||||||||||||||
Genetic Dissection of γ-secretase-dependent and - independent Functions of Presenilin in Regulating Neuronal Cell Cycle and Cell Death 1 Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030 2 Huffington Center on Aging, Baylor College of Medicine, Houston, TX 77030 3 Department of Molecular Physiology and Biophysics, Baylor College of Medicine, Houston, TX 77030 Corresponding Author: Hui Zheng, Huffington Center on Aging, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030. Tel. 713-798-1568; Fax: 713-798-1610; e-mail: huiz/at/bcm.edu The publisher's final edited version of this article is available free at J Neurosci. See other articles in PMC that cite the published article.Abstract Cell cycle markers have been shown to be upregulated and proposed to lead to apoptosis of post-mitotic neurons in Alzheimer’s disease (AD). Presenilin (PS) plays a critical role in AD pathogenesis, and loss of function studies in mice established a potent effect of PS in cell proliferation in peripheral tissues. Whether PS has a similar activity in the neuronal cell cycle has not been investigated. PS exhibits γ-secretase-dependent and -independent functions; the former requires aspartate 257 (D257) as part of the active site, and the latter involves the hydrophilic loop domain encoded by exon 10. We used two novel mouse models, one expressing the PS1 D257A mutation on a postnatal PS conditional knockout background and the other deleting exon 10 of PS1, to dissect the γ-secretase-dependent and -independent activities of PS in the adult CNS. Whereas γ-secretase plays a dominant role in neuronal survival, our studies reveal potent neuronal cell cycle regulation mediated by the PS1 hydrophilic loop. Although neurons expressing cell cycle markers do not directly succumb to apoptosis, they are more vulnerable under stress conditions. Importantly, our data identify a novel pool of cytoplasmic p53 as a downstream mediator of this cellular vulnerability. These results support a model whereby the PS γ-secretase activity is essential in maintaining neuronal viability, and the PS1 loop domain modulates neuronal homeostasis through cell cycle and cytoplasmic p53 control. Keywords: Alzheimer’s disease, presenilin, gamma-secretase, neurodegeneration, cell cycle events, mice Introduction Alzheimer’s disease (AD) is the most common neurodegenerative disease in the aging population. AD is characterized by the deposition of β-amyloid peptides liberated from the amyloid precursor protein (APP), and neurofibrillary tangles composed of hyperphosphorylated tau. In addition to the pathological hallmarks, postmortem investigation reveals that molecules that are traditionally considered cell cycle proteins, such as Cyclins A, B and D, can be detected at early stages of AD preceding neurodegeneration (Yang et al., 2003). This phenomenon, termed cell cycle events (CCE), has also been replicated in AD mouse models with amyloid or tau pathologies (Andorfer et al., 2005; Yang et al., 2006). It has been postulated that unscheduled cell cycle re-entry in post-mitotic neurons is causal for neuronal cell death (reviewed in (Herrup et al., 2004)). Mutations in presenilin genes (PSEN1 and PSEN2) lead to the majority of familial, early onset cases of AD (FAD), establishing a critical role for presenilin (PS) in AD pathogenesis. Among many of the putative pathogenic activities reported, a recent paper documented that neurons harboring the PS1 M146V FAD mutation show Cyclin D1 upregulation, abnormal neuronal cell cycle, and enhanced neuronal apoptosis (Malik et al., 2008). PS is required for γ-secretase cleavage of a multitude of substrates, in particular APP and Notch (De Strooper et al., 1998; De Strooper et al., 1999), and this activity requires the conserved aspartates at the 257 (D257) and 385 (D385) sites (Wolfe et al., 1999). In addition, PS has been shown to exhibit γ-secretase-independent activities through the large hydrophilic loop domain (Baki et al., 2001; Soriano et al., 2001; Kang et al., 2002), and these two events can be biochemically and genetically uncoupled (Xia et al., 2002). In light of the growing list of γ-secretase substrates and diverse pathways PS mediates (reviewed by ((Sisodia and St George-Hyslop, 2002; Kopan and Ilagan, 2004; Vetrivel, 2006), the interpretation of pathogenic mechanisms by the FAD mutations is likely complex. However, increasing evidence supports the notion that the overall effects of these mutations are partial loss of both γ-secretase-dependent and -independent functions (reviewed in (De Strooper, 2007; Shen and Kelleher, 2007)). We reported that loss of PS in peripheral tissues leads to the activation of Cyclin D1, hyperproliferation and skin tumorigenesis (Xia, 2001; Qyang et al., 2004). Inactivation of PS in postnatal neurons results in age-dependent neurodegeneration (Feng et al., 2004; Saura et al., 2004). Using a series of mouse models with either complete PS deficiency or specific disruption of the γ-secretase activity or the hydrophilic loop domain, and complemented with primary neuronal cultures and γ-secretase inhibitors, this study attempts to address the following questions: 1) Does PS regulate neuronal cell cycle events (CCE)? 2) Are the neuronal CCE mediated through γ-secretase-dependent or -independent mechanisms? 3) What is the functional consequence of PS-mediated neuronal CCE? Materials and Methods Mouse Models The references for the various PS alleles are as follows: Exon 4 floxed (fl) allele (Feng et al., 2001); PS1 knockout (Wong et al., 1997); PS2 knockout (Donoviel et al., 1999); PS1 ΔE10 knockin (Deng et al., 2006) and transgenic mice expressing wild-type or D257A mutant human PS1 (Qian et al., 1998; Xia et al., 2002). The CaMKIIα-Cre mice were also described previously (Tsien et al., 1996). The breeding scheme for the generation of PS1 conditional knockout on PS2 null background (PS conditional double knockout or PS cDKO), PS cDKO expressing wild-type human PS1 (PS cDKO; hPS1) or the D257A mutant (PS cDKO; D257A) and their littermate controls are outlined below using hPS1 as an example. Note that PS2−/− mice were normal in all the assays applicable to this study and were used as controls for the PS cDKO animals. The breeding scheme for generating PS1 knockout (PS1−/−), PS1 knockout expressing wild-type or the D257A mutant human PS1 (PS1−/−; hPS1 or PS1−/−; D257A, respectively), and their littermate controls for embryonic neuronal culture studies are diagramed below using hPS1 as an example. Wild-type or heterozygous PS1 littermates were used as controls and no differences between the two genotypes could be detected. Heterozygous interbreeding was set up to create homozygous PS1 ΔE10 and littermate wild-type controls for in vivo and primary culture studies. Table 1 is a summary of the mouse models used for in vivo and neuronal cultures studies.
All animal experiments were performed in accordance with the Baylor College of Medicine Institutional Animal Care and Use Committee and with national regulations and policies. Antibodies and Reagents The following primary antibodies were used: NeuN (1:1000, Chemicon), Cyclin D1 (1:500, Abcam), BrdU (1:100, DAKO Cytomation), p53 (1:500, Abcam), Cyclin A (1:500, Abcam), cleaved caspase-3 (1:500, Abcam) and γ-tubulin (1:10,000, Sigma). The following secondary antibodies were used: Cy3 (1:500, Zymed), Oregon Green (1:500, Molecular Probes), HRP-conjugated anti-mouse and anti-rabbit (1:5000, Vector Laboratories). The γ-secretase inhibitor Compound E was a gift of Dr. Y. Li (Tarassishin et al., 2004). It was dissolved in DMSO and used at a final concentration of 50 nM. Quercetin (Sigma), a potent Cyclin D1 inhibitor, was dissolved in DMSO and used at a final concentration of 10 μM (Malik et al., 2008). 3D MRI Mice were imaged utilizing a 9.4T Bruker Avance Biospec spectrometer with a 21 cm horizontal bore and a 35 mm volume resonator coil (Bruker Biospin, Billerica, MA) and maintained on 1–2% isoflurane during the imaging session. The body temperature of the mice was monitored with a rectal temperature probe and maintained at 37°C using an air heater (Small Animal Instruments, Inc., NY). Additionally, the respiration rate of the animals was monitored with a pressure transducer placed underneath the animals during imaging (Small Animal Instruments, Inc., NY). 3D Rapid Acquisition with Relaxation Enhancement (RARE) image datasets of the brain were obtained for each mouse with RARE factor=8, TR=2000 ms, TE=45.2 ms, FOV=30*30*30 mm, a matrix size of 128*128*128, and 2 signal averages. The acquisition time was 2 hour 16 minute 32 second for each mouse. All pixels attributable to the cortex in the 3D volume were labeled in each slice and volume analysis was performed using the AMIRA software (Mercury Computer Systems, Chelmsford, MA) (Redwine et al., 2003). Cerebellar volume was also quantified as an internal control, which remained constant among all genotypes and across all ages. BrdU injection and brain immunohistochemistry BrdU (Sigma) was dissolved in 0.9% saline. Each animal was injected interperitoneally at a dose of 200 mg/kg daily for four consecutive days (adapted from (Wojtowicz and Kee, 2006)). Mice underwent trans-cardiac perfusion with phosphate buffered saline (PBS) containing heparin and fixed with 4% paraformaldehyde (PFA) at 4°C overnight. After embedding the brains in paraffin wax, sections were cut at 10 μm thickness. The sections were deparaffinized in xylene, then rehydrated with 100%, 95%, 70% ethanol and water. If sections were to be stained with BrdU, treatment with 2N HCl for 20 minutes prior to staining was used to retrieve the BrdU antigen. Protein antigen retrieval was performed using 0.1 M sodium citrate (pH 7.4) for 10 minutes at a constant boil, and sections were cooled at room temperature for 30 minutes thereafter followed by blocking with 5% goat serum for 1 hour. Primary antibodies were applied at 4°C overnight in 2.5% goat serum. Secondary antibodies were applied for 1 hour at 37°C in 2.5% goat serum. The sections were mounted using ProlongGold with DAPI (Invitrogen). Pictures were taken with a Zeiss LSM510 laser scanning confocal microscope equipped with an Axiocam MRC digital camera and the images were analyzed using Image J software (NIH). Quantification of BrdU, Cyclin D1 and Cyclin A positive neurons was performed by counting the number of marker positive neurons per equal area in 15 sections/animal and 3 animals/genotype. Western blot analysis Forebrain samples or cultured cells were homogenized using CHAPS lysis buffer (1% CHAPS, 50 mM Tris pH 7.6, 150 mM NaCl, 2% Sodium Azide) containing complete protease inhibitor cocktail (Roche). After 3 sets of 10 pulses of sonication, the homogenates were spun at 14000 rpm for 15 minutes. Protein concentrations were determined using Bio-Rad Dc Protein Assay (Bio-Rad). 10 μg of protein were loaded on a 10% SDS-PAGE gel run at 100V for 2 hours at room temperature and transferred onto a nitrocellulose membrane (Bio-Rad) at 100V for 1 hour. Membranes were blocked 1 hour using 5% non-fat dry milk in TBS containing 0.1% Tween-20 (TBST, Sigma). Cyclin D1 primary antibody incubation was done in 5% milk in TBST; p53 primary antibody was added to 5% BSA in TBST and incubated overnight at 4°C with constant agitation. After three washes with PBS with 0.1% Tween-20, secondary antibody application was performed at room temperature for 1 hour using 5% milk in TBST followed by three additional washes with PBST. Bands were visualized using Immobilon™ Western ECL system (Millipore). Primary embryonic neuronal cultures and treatment Timed mating was set up and the day when a vaginal plug was observed was considered to be embryonic day 0.5 (E0.5). E15.5 embryos were collected from pregnant females and primary neuronal cultures were prepared from combined neocortex and hippocampi of the embryonic brains. The brain tissues were dissected under a microscope and the cells were mechanically dissociated, resuspended in Neurobasal medium (Invitrogen) with DNase, spun down at 1000×g, resuspended in Neurobasal medium containing 2 mM glutamine and penicillin/streptomycin and plated on poly-D-lysine-coated 60 mm dishes (for Western blotting) or 24-well plates (for all other experiments). Specifically, if cultures were to be used for hydrogen peroxide treatment (H2O2) followed by LDH measurement, the cells were plated at a density of 5×105 cells/well. If the cells were to be used for immunohistochemistry followed by confocal microscopy, the cells were plated at a density of 3×104 cells per well. Twenty-four hours after plating, the medium was replaced with Neurobasal medium containing 1% B27 supplement (Invitrogen) to promote neuronal survival and discourage non-neuronal cell growth. Subsequently the medium was changed every other day. For neurons treated with DMSO or Compound E (dissolved in DMSO), the treatment was begun concurrently with the initial plating of the cells. For LDH measurements, the H2O2 treatment was carried out in neurons cultured 10 days in vitro (DIV) for 24 hours at concentrations ranging from 0–100 μM in 700 μl Neurobasal medium containing 1% B27, DMSO, Quercetin, or Compound E where applicable. Following the treatment, samples, each plated in 50 μl triplicates, were removed and placed in a 96-well plate. 50 μl substrate mix (Cytotox 96, Promega) was added to each well followed by a 30 minute incubation at room temperature protected from light. The reaction was aborted with 50 μl stop solution per well and absorption was measured at 490 nm using a Biotek 96-well plate reader and analyzed using KC junior software. Basal LDH release was obtained from wells with no H2O2 treatment for the 24 hour incubation period for background correction. Total LDH (100%) was obtained by treating wells with lysis solution for one hour prior to LDH measurement. All values are given as % of total LDH release. For time course experiments the neurons were subjected to 1 mM H2O2 treatment for specified times. To inhibit new protein synthesis, cycloheximide at 2 mg/ml (Sigma) was added to the Neurobasal medium and applied concurrently with H2O2. For immunostaining, medium was aspirated off, plates were washed with TBS twice, and 4% PFA was added for 20 minutes in TBST to overnight. Subsequently, the plates were washed twice with TBST (0.1% Triton-X100) and incubated for 20 minutes to permeabilize the cells. Non-specific interactions were blocked with 10% goat serum in TBST. The primary antibody incubation was performed in 5% TBST at 4 °C overnight followed by three TBST washes and incubation with secondary antibody in 5% TBST for 1 hour at room temperature. Images were acquired using a Zeiss LSM 520 laser confocal microscope and analyzed using Image J software. Cyclin D1 positive neurons were counted in each field using Image J nuclei counter. Total neuronal counts were obtained per section and % Cyclin D1 positive neurons were calculated. Percent nuclear p53 was obtained using Image J to attain nuclear and cytoplasmic staining intensity in a set area (50×50 pixels). Statistical analysis All statistical analysis was performed using the Student’s t-test. *p<0.05, **p<0.01, ***p<0.001. Data are presented as average ± SEM (standard error of mean). Results γ-secretase is the major but not the sole contributor to neuronal viability Previous studies have established that conditional inactivation of PS1 in postnatal forebrain neurons (PS1 cKO) by CaMKIIα-Cre transgene expression resulted in only subtle phenotypes (Feng et al., 2001; Yu et al., 2001). However, deleting PS2 on conditional PS1 null background (herein referred to as PS double conditional knockout or PS cDKO) led to profound neuronal cell loss (Feng et al., 2004; Saura et al., 2004). Magnetic Resonance Imaging (MRI) of live animals was used to quantify the degree of neurodegeneration by measuring the cortical volumes of control and PS cDKO mice at 2, 6 and 12 months of age (Figure 1A
To determine the contribution of γ-secretase to neuronal survival, we expressed either the human wild-type PS1 transgene (hPS1, line 17-3) or the γ-secretase deficient transgene PS1 D257A (D257A, line 7) with similar levels of expression onto PS cDKO background (PS cDKO; hPS1 or PS cDKO; D257A), respectively. The PS1 D257A mutant has been shown to be defective in γ-secretase processing while preserving γ-secretase-independent activities (Xia et al., 2002). MRI analysis revealed that expression of the wild-type human PS1 resulted in complete rescue as the cortical volumes were indistinguishable from that of the control animals (Figure 1, C and D Neuronal cell cycle activation is γ-secretase-independent and is not sufficient to cause neurodegeneration Neuronal cell cycle events (CCE) have been observed in various neurodegenerative conditions including AD and have been proposed to trigger neuronal cell loss. Our previous studies identified a potent role for PS in promoting cell proliferation in peripheral tissues (Xia, 2001; Qyang et al., 2004), and this activity may involve the PS1 hydrophilic loop domain and the β-catenin/Cyclin D1 pathway (Soriano et al., 2001; Kang et al., 2002). To examine whether PS plays a similar role in the neuronal cell cycle and whether CCE contribute to neuronal cell death, we performed Cyclin D1 immunostaining in PS cDKO mice and PS cDKO expressing wild-type or D257A mutant PS1 (Figure 2A
To further evaluate the functional consequences of neuronal CCE, we examined BrdU incorporation in PS cDKO and PS1 ΔE10 animals, which either do or do not possess neurodegenerative phenotype respectively. Daily BrdU injections for four days followed by immunostaining either 1, 7 or 14 days later revealed that, interestingly, BrdU positive neurons could only be detected in PS cDKO animals (Figure 3A
Cell cycle events promote neuronal cell death under stress conditions The above in vivo studies suggest that loss of γ-secretase is a major contributor to the neurodegenerative phenotype seen in PS cDKO animals. However, considerable rescue by expression of the γ-secretase defective PS1 D257A mutant indicates a role for γ-secretase-independent domains. While activation of neuronal CCE is an obvious candidate for the γ-secretase-independent activity, our in vivo results clearly show that CCE alone are not sufficient to cause neurodegeneration. To seek further understanding of the in vivo phenotypes and to explore the functional consequences of neuronal CCE, we employed the use of primary neuronal cultures. The early embryonic lethality of PS1 and PS2 double null embryos precludes the derivation of PS deficient neuronal cultures (Donoviel et al., 1999; Herreman et al., 1999). However, PS1 is known to be the major presenilin during development (Shen et al., 1997; Wong et al., 1997), and neurons derived from PS1 null animals have been extensively used to study PS function. We therefore chose to culture neurons isolated from embryonic day 15.5 (E15.5) of the following PS1 genotypes (summarized in Table 1): PS1 knockout (PS1−/−), PS1 knockout expressing wild-type or D257A mutant of human PS1 (PS1−/−; hPS1 or PS1−/−; D257A, respectively), as well as homozygous PS1 E10. Examination of neuronal morphology and measurement of neuronal viability using the lactate dehydrogenase (LDH) release assay failed to detect overt differences in any of the genotypes when compared with littermate controls (data not shown). We first assessed cell cycle marker expression in the above neurons cultured 5 days in vitro (DIV). Strikingly, immunostaining showed that while control neurons lacked Cyclin D1, prominent Cyclin D1 expression could be detected in the nucleus and cytoplasm in ~85% of PS1−/− and PS1 ΔE10 neurons (Figure 4A
Although the basal survival of PS1 null and PS1 ΔE10 neurons was not affected as compared with their littermate controls, we reasoned that lack of γ-secretase or abnormal CCE may render them susceptible under stress conditions. We therefore investigated the effects of these functional domains on neuronal survival by treating the cultured neurons with 25–100 μM of hydrogen peroxide (H2O2) and measuring the degree of cell death using the LDH release assay (Figure 5A
The cell culture studies indicate that as found in vivo, loss of γ-secretase is the major factor rendering the neurons susceptible to cytotoxic stress. However, under high stress (75 and 100 μM H2O2) conditions, both γ-secretase and the hydrophilic loop are required for neuronal integrity. Our data suggest that rescue of neuronal CCE by the PS1 D257A mutant may be responsible for the partial rescue of the neurodegenerative phenotype in PS cDKO; D257A animals as compared to PS cDKO mice. p53 is a downstream effecter of the PS loop domain The tumor suppressor p53 is a stress-induced protein with a well-established role in cell cycle checkpoint control. It is also the most important determinant of neuronal viability (reviewed by (Miller et al., 2000)). Since PS has been shown to modulate p53 expression (Alves da Costa et al., 2002; Alves da Costa et al., 2003; Alves da Costa et al., 2006), we investigated whether basal p53 expression is altered as a function of PS1 genotypes. Surprisingly, we found that both PS1−/− and PS1 ΔE10 neurons showed prominent expression of p53 protein under non-stimulated conditions (Figure 6A
Since cell death induction by p53 likely requires nuclear localization, we wondered whether the cytoplasmic p53 present in PS1 null and PS1 ΔE10 neurons was capable of translocating to the nucleus under stress conditions. Because p53 is known to be induced by stress, we treated the neurons with cycloheximide, a potent protein synthesis inhibitor, following the H2O2 induction to prevent new p53 synthesis and to allow specific follow-up of the cytoplasmic pool of p53. Inhibition of new p53 synthesis was demonstrated by the absence of p53 in control neurons after 60 minutes of H2O2 treatment (data not shown). While p53 was exclusively cytoplasmically localized prior to H2O2 treatment (Figure 7
Discussion Presenilin plays a pivotal role in AD pathogenesis as mutations in PSEN1 and PSEN2 lead to early onset of familial AD (FAD). The large number (over 150 in PSEN1 alone) and widespread distribution of the FAD mutations are indicative of a partial loss of function by the disease-causing mutations, and this interpretation is supported by abundant experimental evidence. Originally discovered as part of the γ-secretase complex essential for APP and Notch processing, PS has been shown to be responsible for the intramembraneous cleavage of an increasing list of type I transmembrane proteins (Kopan and Ilagan, 2004; Wang et al., 2006). In addition to this important γ-secretase activity, which requires the aspartates at the 257 and 385 sites of PS1 (Wolfe et al., 1999), PS has been reported to possess γ-secretase-independent functions, including the regulation of β-catenin/Cyclin D1 (Soriano et al., 2001; Kang et al., 2002), intracellular protein turnover (Esselens et al., 2004; Wilson et al., 2004; Repetto et al., 2007) and ER calcium (Tu et al., 2006). In both γ-secretase-dependent and -independent activities, FAD-linked presenilin mutations have been shown to result in partial loss of function (reviewed in (De Strooper, 2007; Shen and Kelleher, 2007)). Accordingly, studying the mechanisms underlying the physiological functions of PS will provide pathogenic insights. Besides the pathological hallmarks of β-amyloid plaques and neurofibrillary tangles, aberrant activation of cell cycle markers can be found in post-mitotic neurons in AD, and these cell cycle events (CCE) precede neuronal cell death (Yang et al., 2003). Although cell cycle reentry in post-mitotic neurons has been postulated to lead to neurodegeneration in AD, this cause-effect relationship cannot be established in humans. We reported earlier that loss of PS1 or reduction of total PS dosage results in Cyclin D1 activation and hyperproliferation in peripheral tissues (Xia, 2001; Qyang et al., 2004). Mice with postnatal inactivation of PS develop neurodegeneration (Feng et al., 2004; Saura et al., 2004). These data combined prompted us to hypothesize that PS may have a similar role in modulating neuronal cell cycle, and that neuronal CCE may contribute to the neurodegenerative phenotype seen in PS conditional knockout mice. Immunohistochemical staining showed that, indeed, significant activation of cell cycle markers including Cyclin D1 and Cyclin A can be detected accompanying neurodegeneration in PS cDKO animals. However, CCE were also evident in PS1 ΔE10 brains. The absence of neuronal cell loss in these animals argues against a causal role of CCE in neuronal cell death. This assessment is further substantiated by genetic rescue demonstrating that expression of PS1 D257A on PS cDKO background can completely suppress CCE despite significant persistence of neurodegeneration. As such, neuronal viability is primarily determined by PS γ-secretase activity whereas neuronal CCE, activated by the loss of the PS1 hydrophilic loop domain, are not obligatory for neurodegeneration. Nevertheless, partial rescue of the cortical volume by PS1 D257A indicates that γ-secretase-independent activity, which has been shown to be preserved in the D257A mutant (Xia et al., 2002), also plays a functional role in neuronal survival. Previous studies have established a role of the PS1 loop domain in regulating β-catenin stability and downstream Cyclin D1 transcription (Soriano et al., 2001; Kang et al., 2002; Kang et al., 2005). Therefore, activation of Cyclin D1 in PS loss of function and PS1 ΔE10 brains is likely mediated through deregulated β-catenin signaling. Consistent with a partial loss of function mechanism, a recent report showed that neurons derived from PS1 M146V FAD knockin mice exhibit impaired β-catenin/Cyclin D1 signaling pathway and abnormal neuronal cell cycle profiles (Malik et al., 2008). Since expression of Cyclins can be either the trigger of or in response to the cell cycle and are often co-activated, it is possible that Cyclin A is ectopically elevated in response to Cyclin D1 and impaired cell cycle control. It is interesting to note that although CCE are prominent features in both PS cDKO and PS1 ΔE10 neurons, they show different BrdU profiles. While a subset of PS cDKO neurons are BrdU positive, the same BrdU injection protocol failed to label any neurons in PS1 ΔE10 brains. These results indicate that additional insults are required for the CCE positive neurons to undergo active DNA synthesis. Even neurons incorporating BrdU do not succumb to immediate death as revealed by the retention of most of the labeled neurons 7 days post-injection. However, approximately half of the BrdU-positive neurons are lost 14 days after injection, and the remaining ones exhibit abnormal morphology and approximately 80% of the cells are positive for active caspase-3, suggesting that the BrdU-incorporating neurons are destined to die over a period of time. Although caspase-3 is known to be a cytoplasmic protein, nuclear localization of cleaved and active caspase-3 has been reported in multiple cell death systems, in particular in a rat model of Parkinson’s disease (Jeon et al., 1999). The nuclear staining of active caspase-3 in PS cDKO mice suggests that PS deficiency-induced neurodegeneration likely involves activation of nuclear targets of caspase-3. Our results combined support a model whereby CCE represent an early stage of neuronal impairment. A series of downstream insults is necessary to trigger the CCE positive neurons to re-enter the cell cycle, leading to eventual neuronal cell death. This model is compatible with the fact that CCE precedes neuronal cell loss in human AD (Yang et al., 2003), and that cell cycle markers are activated in the absence of neurodegeneration in APP transgenic mice (Yang et al., 2006). Consistent with this “multiple insult” hypothesis, our genetic and pharmacological studies using primary neuronal cultures reveal that loss of PS1 does not affect basal neuronal survival. It rather renders the neurons more susceptible to oxidative stress, and multiple PS-mediated pathways are involved in response to stress levels. In particular, at low H2O2 concentration (25 μM), neuronal death is conferred by the loss of γ-secretase. However, both γ-secretase-dependent and -independent activities are necessary to support neuronal survival under high stress conditions (75 and 100 μM H2O2) as demonstrated by the significantly increased LDH release in PS1 ΔE10 neurons. The mechanisms mediating the neuronal viability by the two PS domains are distinct. While defective PS substrate processing and signaling should be considered as the cause for the neuronal vulnerability in the absence of γ-secretase, neuronal CCE and cytoplasmic p53 accumulation likely trigger γ-secretase-independent neuronal cell death. p53-immunoreactivity can be detected in degenerating neurons of AD and its activation has been shown to precede neuronal cell death (Culmsee et al., 2003). PS and other components of the γ-secretase complex have been reported to modulate the expression of p53, and this pathway has been proposed to mediate PS-dependent cell death (Alves da Costa et al., 2002; Alves da Costa et al., 2003; Alves da Costa et al., 2006; Dunys et al., 2007). Motivated by these findings, we examined p53 levels in our various PS alleles. Surprisingly, we did not see a significant regulation of p53 by γ-secretase. Instead, we uncovered a novel cytoplasmic pool of p53 that is subject to PS1 loop regulation. This pool is inactive under resting conditions. However, it is capable of translocating to the nucleus under stress conditions and mediates neuronal apoptosis. The fact that aberrant p53 expression can be blocked by the cell cycle inhibitor quercetin places p53 downstream of neuronal CCE. This γ-secretase-independent regulation of p53 is different from work published by the Checler group (Alves da Costa et al., 2002; Alves da Costa et al., 2003; Alves da Costa et al., 2006; Checler et al., 2007; Dunys et al., 2007), which documented a requirement for the γ-secretase complex and involvement of APP-mediated transcriptional regulation. While the reason for this discrepancy is not currently understood, it is important to point out that p53 is a stress induced protein and is subject to multiple levels of regulation through multiple pathways. Since p53 plays a critical role in neuronal survival, the fact that the PS1 null neurons are more vulnerable compared to that of PS1 ΔE10 despite similar accumulation of the cytoplasmic p53 supports the idea that additional mechanisms, which may involve APP-mediated p53 transcription as reported by the Checler group, contribute to the higher H2O2 induced cell death in PS1-deficient neurons. Our data combined support a model in which distinct genetic and biochemical pathways govern γ-secretase-dependent and -independent functions of PS, and these two pathways differentially contribute to neuronal vulnerability. While loss of γ-secretase activity and its associated substrate processing and signaling plays a major role in the neurodegenerative process, absence of the hydrophilic loop domain leads to neuronal CCE and cytoplasmic p53 accumulation, likely sensitizing the neurons to exogenous and potentially endogenous insults, and leading to stress-induced cell death. This model may have direct implications for AD and other neurodegenerative diseases in general. Post-mitotic neurons are exposed to various environmental and intrinsic insults throughout their lifetime. While each individual insult renders the neurons vulnerable, we propose that the accumulation of multiple damages over a threshold level is required for the neurons to degenerate. It is conceivable that PS deficiency, PS FAD mutations, genetic risk factors such as ApoE4, or aging provides intrinsic insults or increases the sensitivity to environmental insults. Each factor contributes to neuronal vulnerability, the combination of which lead to neurodegeneration and AD pathogenesis. Supp1 Click here to view.(312K, doc) Acknowledgments We thank Drs. S. Sisodia (U. Chicago) and S. Tonegawa (MIT) for the PS1 floxed mice and the CaMKIIα-Cre transgenic line, respectively, and Dr. Y. Li (Memorial Sloan Kettering Cancer Center) for Compound E. We are grateful to N. Aithmitti for expert technical support and members of the Zheng laboratory for constructive discussions. We acknowledge R. Atkinson and the Mental Retardation and Developmental Disabilities Research Center at Baylor College of Medicine for confocal imaging support. This work was supported by grants from NIH (AG20670, AG21141 and NS40039 to HZ and AG29977 to RGP). V. K.-M. is a Baylor Research Advocates for Student Scientists Scholar and trainee of the NIH training grant T32 GM08307. References
|
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||||||||||||||||||||||
J Neurosci. 2003 Apr 1; 23(7):2557-63.
[J Neurosci. 2003]J Neurosci. 2005 Jun 1; 25(22):5446-54.
[J Neurosci. 2005]J Neurosci. 2006 Jan 18; 26(3):775-84.
[J Neurosci. 2006]J Neurosci. 2004 Oct 20; 24(42):9232-9.
[J Neurosci. 2004]Cell Cycle. 2008 Mar 1; 7(5):637-46.
[Cell Cycle. 2008]Nature. 1998 Jan 22; 391(6665):387-90.
[Nature. 1998]Nature. 1999 Apr 8; 398(6727):518-22.
[Nature. 1999]Nature. 1999 Apr 8; 398(6727):513-7.
[Nature. 1999]Proc Natl Acad Sci U S A. 2001 Feb 27; 98(5):2381-6.
[Proc Natl Acad Sci U S A. 2001]J Cell Biol. 2001 Feb 19; 152(4):785-94.
[J Cell Biol. 2001]Proc Natl Acad Sci U S A. 2001 Sep 11; 98(19):10863-8.
[Proc Natl Acad Sci U S A. 2001]Biochemistry. 2004 May 11; 43(18):5352-9.
[Biochemistry. 2004]Proc Natl Acad Sci U S A. 2004 May 25; 101(21):8162-7.
[Proc Natl Acad Sci U S A. 2004]Neuron. 2004 Apr 8; 42(1):23-36.
[Neuron. 2004]Neuron. 2001 Dec 6; 32(5):911-26.
[Neuron. 2001]Nature. 1997 May 15; 387(6630):288-92.
[Nature. 1997]Genes Dev. 1999 Nov 1; 13(21):2801-10.
[Genes Dev. 1999]J Neurosci. 2006 Apr 5; 26(14):3845-54.
[J Neurosci. 2006]Neuron. 1998 Mar; 20(3):611-7.
[Neuron. 1998]Proc Natl Acad Sci U S A. 2004 Dec 7; 101(49):17050-5.
[Proc Natl Acad Sci U S A. 2004]Cell Cycle. 2008 Mar 1; 7(5):637-46.
[Cell Cycle. 2008]Proc Natl Acad Sci U S A. 2003 Feb 4; 100(3):1381-6.
[Proc Natl Acad Sci U S A. 2003]Nat Protoc. 2006; 1(3):1399-405.
[Nat Protoc. 2006]Neuron. 2001 Dec 6; 32(5):911-26.
[Neuron. 2001]Neuron. 2001 Sep 13; 31(5):713-26.
[Neuron. 2001]Proc Natl Acad Sci U S A. 2004 May 25; 101(21):8162-7.
[Proc Natl Acad Sci U S A. 2004]Neuron. 2004 Apr 8; 42(1):23-36.
[Neuron. 2004]Proc Natl Acad Sci U S A. 2002 Jun 25; 99(13):8760-5.
[Proc Natl Acad Sci U S A. 2002]Proc Natl Acad Sci U S A. 2001 Sep 11; 98(19):10863-8.
[Proc Natl Acad Sci U S A. 2001]Biochemistry. 2004 May 11; 43(18):5352-9.
[Biochemistry. 2004]J Cell Biol. 2001 Feb 19; 152(4):785-94.
[J Cell Biol. 2001]Cell. 2002 Sep 20; 110(6):751-62.
[Cell. 2002]J Neurosci. 2006 Apr 5; 26(14):3845-54.
[J Neurosci. 2006]Genes Dev. 1999 Nov 1; 13(21):2801-10.
[Genes Dev. 1999]Proc Natl Acad Sci U S A. 1999 Oct 12; 96(21):11872-7.
[Proc Natl Acad Sci U S A. 1999]Cell. 1997 May 16; 89(4):629-39.
[Cell. 1997]Nature. 1997 May 15; 387(6630):288-92.
[Nature. 1997]Proc Natl Acad Sci U S A. 2004 Dec 7; 101(49):17050-5.
[Proc Natl Acad Sci U S A. 2004]Biochem Biophys Res Commun. 2005 Mar 4; 328(1):227-34.
[Biochem Biophys Res Commun. 2005]Cell Cycle. 2008 Mar 1; 7(5):637-46.
[Cell Cycle. 2008]Cell Death Differ. 2000 Oct; 7(10):880-8.
[Cell Death Differ. 2000]Proc Natl Acad Sci U S A. 2002 Mar 19; 99(6):4043-8.
[Proc Natl Acad Sci U S A. 2002]J Biol Chem. 2003 Apr 4; 278(14):12064-9.
[J Biol Chem. 2003]J Neurosci. 2006 Jun 7; 26(23):6377-85.
[J Neurosci. 2006]Nat Rev Mol Cell Biol. 2004 Jun; 5(6):499-504.
[Nat Rev Mol Cell Biol. 2004]Proc Natl Acad Sci U S A. 2006 Jan 10; 103(2):353-8.
[Proc Natl Acad Sci U S A. 2006]Nature. 1999 Apr 8; 398(6727):513-7.
[Nature. 1999]J Cell Biol. 2001 Feb 19; 152(4):785-94.
[J Cell Biol. 2001]Cell. 2002 Sep 20; 110(6):751-62.
[Cell. 2002]J Neurosci. 2003 Apr 1; 23(7):2557-63.
[J Neurosci. 2003]Proc Natl Acad Sci U S A. 2001 Sep 11; 98(19):10863-8.
[Proc Natl Acad Sci U S A. 2001]Biochemistry. 2004 May 11; 43(18):5352-9.
[Biochemistry. 2004]Proc Natl Acad Sci U S A. 2004 May 25; 101(21):8162-7.
[Proc Natl Acad Sci U S A. 2004]Neuron. 2004 Apr 8; 42(1):23-36.
[Neuron. 2004]Proc Natl Acad Sci U S A. 2002 Jun 25; 99(13):8760-5.
[Proc Natl Acad Sci U S A. 2002]J Cell Biol. 2001 Feb 19; 152(4):785-94.
[J Cell Biol. 2001]Cell. 2002 Sep 20; 110(6):751-62.
[Cell. 2002]J Biol Chem. 2005 Sep 9; 280(36):31537-47.
[J Biol Chem. 2005]Cell Cycle. 2008 Mar 1; 7(5):637-46.
[Cell Cycle. 2008]J Neurochem. 1999 Jul; 73(1):322-33.
[J Neurochem. 1999]J Neurosci. 2003 Sep 17; 23(24):8586-95.
[J Neurosci. 2003]Proc Natl Acad Sci U S A. 2002 Mar 19; 99(6):4043-8.
[Proc Natl Acad Sci U S A. 2002]J Biol Chem. 2003 Apr 4; 278(14):12064-9.
[J Biol Chem. 2003]J Neurosci. 2006 Jun 7; 26(23):6377-85.
[J Neurosci. 2006]J Biol Chem. 2007 Apr 6; 282(14):10516-25.
[J Biol Chem. 2007]